Novel Therapeutic Approaches in the Treatment of Multiple Myeloma
Last Modified: April 6, 2005
Conference Dates: May 19-20, 2005
Conference Location: Best Western Boston, The Inn at Longwood Medical, 342 Longwood Avenue, Boston, MA
Sponsoring Group: Dana-Farber/Partners CancerCare, Harvard Medical School, Multiple Myeloma Research Foundation
Conference Web Page URL: www.multiplemyeloma.org/medical_programs
- Indentify the prognostic indicators and diagnostic approaches to multiple myeloma.
- Discuss the latest advances in stem cell transplantation, treatments for bone disease, and supportive care management.
- Describe the role and appropriate use of novel treatments for multiple myeloma throughout the disease progression.
Who Should Attend: Patients (May 19); Hematologists, Medical Oncologists, Oncology Nurses, Internists with Newly Diagnosed Patients
Registration Information: Patient Program, May 19: Contact the MMRF at 203-972-1250 or visit www.mulitplemyeloma.org/medical_programs. Professional Program, May 20: www.cancercare.harvard.edu
Conference Fees: Free Patient Program, $25 Professional Registration
Continuing Education: Yes. 4 category 1 credits available for physicians.
ASH: Novel Drug Beneficial in Multiple Myeloma
May 24, 2015 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a hig
Frequently Asked Questions
National Cancer Institute
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!